Psyence Biomedical Ltd. (PBM) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 632.1K | 754.38K | 512.09K | 771.49K | 1.74M | -281.46K | 293.02K | 326.9K | 254.79K | 45.06K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 556.97K | 184.7K | 512.09K | 771.49K | 762.74K | 242.15K | 293.02K | 326.9K | 254.79K | 45.06K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 75.14K | 0 | 0 | 0 | 977.92K | 1.85K | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 569.67K | 0 | 0 | 0 | -525.46K | 0 | 0 | 0 | 0 |
| Operating Income | -632.1K | -176.16K | -678.39K | -1.04M | -510.93K | -244K | -293.02K | -326.9K | -254.8K | -45.06K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -23.72% | 27.8% | -131.52% | -219.2% | -100.52% | -441.5% | - | - | - | - |
| EBITDA | -631.98K | -877.22K | -83.25K | -33.12K | 3.02M | 1.05M | 2.63M | 3.69M | 10.59M | -45.06K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -120.9% | -183.45% | -103.16% | -100.9% | -71.45% | 2432.89% | - | - | - | - |
| D&A (Non-Cash Add-back) | 120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -632.22K | -877.22K | -83.25K | -33.12K | -1.74M | 1.05M | 2.63M | 3.69M | 10.59M | -45.06K |
| Net Interest Income | -11.47K | -27.57K | 187.84K | 485.6K | 2.63M | -3.23M | 115.55K | 6.29K | 2.42K | 0 |
| Interest Income | 0 | 170.69K | 187.84K | 485.6K | 2.63M | -3.23M | 115.55K | 6.29K | 2.42K | 0 |
| Interest Expense | 0 | 27.57K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -24.13M | -133.52K | 449.25K | 747K | 2.76M | -669 | 2.34M | 3.28M | 8.56M | 3 |
| Pretax Income | -24.76M | -309.68K | -62.84K | -24.49K | 2.25M | -244.67K | 2.04M | 2.95M | 8.31M | -45.06K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -24.76M | -877.22K | -62.84K | -24.49K | 2.25M | 766.84K | 2.04M | 2.95M | 8.31M | -45.06K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -1200.36% | -214.39% | -103.07% | -100.83% | -72.92% | 1801.93% | - | - | - | - |
| Net Income (Continuing) | -24.76M | -877.22K | -62.84K | -24.49K | 2.25M | -244.67K | 2.04M | 2.95M | 8.31M | -45.06K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.85 | -0.08 | -0.01 | -0.00 | 0.07 | 0.03 | 0.07 | 0.10 | 0.25 | -0.00 |
| EPS Growth % | -2785.05% | -413.01% | -110.89% | -102.1% | -72.44% | - | - | - | - | - |
| EPS (Basic) | -1.85 | -0.08 | -0.01 | -0.00 | 0.07 | 0.03 | 0.07 | 0.10 | 0.25 | -0.00 |
| Diluted Shares Outstanding | 13.39M | 7.69M | 8.04M | 11.43M | 32.67M | 28.54M | 28.54M | 28.54M | 32.67M | 32.75M |
| Basic Shares Outstanding | 13.39M | 7.69M | 8.04M | 11.43M | 32.67M | 28.54M | 28.54M | 28.54M | 32.67M | 32.75M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |